Drug Substance Review - ANDA (22/28) Generic Drugs Forum 2017

Generic Drug Product Quality Review (23/28) Generic Drugs Forum 2017

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

Microbiology Assessment: Recommendations for Nonsterile Products (1of6) Mar. 15, 2017

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

Roundtable on PMTA Submissions for ENDS Products

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

Safety Considerations for Patient Instructions to Minimize Medication Errors (9/9) Labeling 2017

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Direct: Combating Rare Diseases at the FDA